```
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8
 NEWS X25       X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:47:30 ON 27 FEB 2007

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:47:52 ON 27 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 FEB 2007  HIGHEST RN 923293-79-2
DICTIONARY FILE UPDATES:  26 FEB 2007  HIGHEST RN 923293-79-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s dalbavancin
L1             8 DALBAVANCIN

=> file ca
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         5.40       5.61

FILE 'CA' ENTERED AT 14:48:14 ON 27 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 22 Feb 2007 VOL 146 ISS 10
FILE LAST UPDATED: 22 Feb 2007 (20070222/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1
L2 79 L1

=> s l2 and protein
1925041 PROTEIN
L3 6 L2 AND PROTEIN

=> d l3 1-6

L3 ANSWER 1 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 146:38160 CA
TI Dalbavancin: a novel lipoglycopeptide antibacterial
AU Pope, Scott D.; Roecker, Andrew M.
CS Department of Pharmacy, Carolinas Medical Center, Charlotte, NC, USA
SO Pharmacotherapy (2006), 26(7), 908-918
CODEN: PHPYDQ; ISSN: 0277-0008
PB Pharmacotherapy Publications
DT Journal; General Review
LA English
RE.CNT 85 THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 142:370634 CA
TI Differential inhibition of Staphylococcus aureus PBP2 by glycopeptide antibiotics
AU Leimkuhler, Catherine; Chen, Lan; Barrett, Dianah; Panzone, Gianbattista; Sun, Binyuan; Falcone, Brian; Oberthuer, Markus; Donadio, Stefano; Walker, Suzanne; Kahne, Daniel
CS Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, 02138, USA
SO Journal of the American Chemical Society (2005), 127(10), 3250-3251
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 141:28638 CA
TI Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
IN Cavaleri, Marco; Colombo, Luigi; Henkel, Timothy; Jabes, Daniela; Malabarba, Adriano; Mosconi, Giorgio; Stogniew, Martin; White, Richard J.
PA Vicuron Pharmaceuticals Inc., USA
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046196	A2	20040603	WO 2003-US36399	20031114
	WO 2004046196	A3	20040819		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003299561	A1	20040615	AU 2003-299561	20031114
	US 2005004011	A1	20050106	US 2003-713924	20031114
	US 2005130909	A1	20050616	US 2003-714166	20031114
	CN 1711102	A	20051221	CN 2003-80103406	20031114
	US 2005032721	A1	20050210	US 2004-942197	20040915
	US 2005130914	A1	20050616	US 2004-942604	20040915
PRAI	US 2002-427654P	P	20021118		
	US 2003-485694P	P	20030708		
	US 2003-495048P	P	20030813		
	US 2003-496483P	P	20030819		
	US 2003-714261	A1	20031114		
	WO 2003-US36399	W	20031114		
	US 2004-828483	A1	20040416		

L3 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 140:369930 CA
TI Nonomuraea dbv gene cluster for biosynthesis of dalbavancin precursor, antibiotic A40926
IN Donadio, Stefano; Sosio, Margherita; Beltrametti, Fabrizio
PA Vicuron Pharmaceuticals, Inc., USA
SO Eur. Pat. Appl., 165 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1413626	A1	20040428	EP 2002-23597	20021023
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CA 2501393	A1	20040506	CA 2003-2501393	20031015
	WO 2004038025	A2	20040506	WO 2003-EP11398	20031015
	WO 2004038025	A3	20040729		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003294693	A1	20040513	AU 2003-294693	20031015
	EP 1578972	A2	20050928	EP 2003-785622	20031015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

	CN 1732263	A	20060208	CN 2003-80107411	20031015
	JP 2006516885	T	20060713	JP 2004-545854	20031015
PRAI	EP 2002-23597	A	20021023		
	WO 2003-EP11398	W	20031015		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 140:54179 CA
TI The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by Nonomuraea species
AU Sosio, Margherita; Stinchi, Sofia; Beltrametti, Fabrizio; Lazzarini, Ameriga; Donadio, Stefano
CS Vicuron Pharmaceuticals, Gerenzano, 21040, Italy
SO Chemistry & Biology (2003), 10(6), 541-549
CODEN: CBOLE2; ISSN: 1074-5521
PB Cell Press
DT Journal
LA English
RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 135:254360 CA
TI In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent
AU Jones, R. N.; Biedenbach, D. J.; Johnson, D. M.; Pfaller, M. A.
CS The Jones Microbiology Institute, North Liberty, IA, 52317, USA
SO Journal of Chemotherapy (Firenze, Italy) (2001), 13(3), 244-254
CODEN: JCHEEU; ISSN: 1120-009X
PB E.I.F.T. srl
DT Journal
LA English
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3 1-6 an ab

L3 ANSWER 1 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 146:38160 CA
AB A review. Dalbavancin is a new lipoglycopeptide antibacterial possessing in vitro activity against a variety of gram-pos. pathogens. Against methicillin-susceptible and methicillin-resistant Staphylococcus aureus, it has demonstrated favorable min. inhibitory concentration ranges compared with those of currently available agents. Dalbavancin is highly protein bound (> 90%), which may contribute to its prolonged half-life of 149-300 h. Because of this long half-life, once-weekly dosing strategies have been used in clin. trials. Efficacy and tolerability have been demonstrated in a wide variety of animal infection models. Clin. success and safety have been shown in phase II and III trials for skin and soft-tissue infections and a phase II trial for catheter-related bloodstream infections. In these trials with vancomycin, linezolid, and various β-lactams as comparators, comparable results have been reported. The results of further phase III trials are anxiously awaited and will more clearly define the clin. role of this novel agent.

L3 ANSWER 2 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 142:370634 CA
AB Glycopeptide antibiotics prevent maturation of the bacterial cell wall by binding to the terminal D-alanyl-D-alanine moiety of peptidoglycan precursors, thereby inhibiting the enzymes involved in the final stages of peptidoglycan synthesis. However, there are significant differences in the biol. activity of particular glycopeptide derivs. that are not related

to their affinity for D-Ala-D-Ala. The authors compare the ability of vancomycin and a set of clin. relevant glycopeptides to inhibit Staphylococcus aureus PBP2 (penicillin binding protein), the major transglycosylase in a clin. relevant pathogen, S. aureus. They report expts. suggesting that activity differences between glycopeptides against this organism reflect a combination of substrate binding and secondary interactions with key enzymes involved in peptidoglycan synthesis.

L3 ANSWER 3 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 141:28638 CA
AB The invention provides methods and compns. for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-pos. bacterial infection of skin and soft tissue, under conditions where a protein-dalbavancin complex forms, or administering a protein-dalbavancin complex. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.

L3 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 140:369930 CA
AB The present invention relates to the field of antibiotics and more specifically to the isolation of nucleic acid mols. that code for the biosynthetic pathway of the glycopeptide antibiotic A40926. Disclosed are the functions of the gene products involved in A40926 production The present invention provides biosynthetic genes that code for A40926 production, the encoded polypeptides, the recombinant vectors comprising the nucleic acid sequences that encode said polypeptides, the host cells transformed with said vectors and methods for producing glycopeptide antibiotics using said transformed host cells, including methods for producing A40926, a precursor thereof, a derivative thereof or a modified glycopeptide different from A40926 or a precursor thereof.

L3 ANSWER 5 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 140:54179 CA
AB The glycopeptide A40926 is the precursor of dalbavancin, a second-generation glycopeptide currently under clin. development. The dbv gene cluster, devoted to A40926 biosynthesis, was isolated and characterized from the actinomycete Nonomuraea species ATCC39727. From sequence anal., 37 open reading frames (ORFs) participate in A40926 biosynthesis, regulation, resistance, and export. Of these, 27 ORFs find a match in at least one of the previously characterized glycopeptide gene clusters, while 10 ORFs are, so far, unique to the dbv cluster. Putative genes could be identified responsible for some of the tailoring steps (attachment of glucosamine, sugar oxidation, and mannosylation) expected during A40926 biosynthesis. After constructing a Nonomuraea mutant by deleting ORFs 8 to 10, the novel compound dechloromannosyl-A40926 aglycon was isolated.

L3 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN
AN 135:254360 CA
AB BI 397, a semi-synthetic amide derivative of the exptl. glycopeptide, MDL 62,476 (A40926), has excellent in vitro activity against a wide range of Gram-pos. organisms. In this extensive study, 630 contemporary (1998-2000) Gram-pos. isolates were selected from various resistance surveillance studies for their resistance patterns to fluoroquinolones, macrolides-lincosamides-streptogramins, β-lactams and glycopeptide agents. The BI 397 spectrum of activity was similar to that of other glycopeptides with a MIC90 of ≤0.5 μg/mL for all tested isolates with the exception of vancomycin-resistant enterococci Van A; (MIC90, 32 μg/mL). BI 397 was more potent than vancomycin and teicoplanin against Staphylococcus aureus (2- to 8-fold), β-hemolytic streptococci (equal

to >16-fold), viridans group streptococci (equal to >32-fold), and Corynebacterium spp. including C. jeikeium (8- to >16-fold). BI 397 was also more active than quinupristin/dalfopristin against all Gram-pos. organisms tested with the exception of oxacillin-susceptible S. aureus, against which it had equal activity. BI 397 has little activity against Haemophilus influenzae (MIC90, 64 µg/mL) or other Gram-neg. bacilli (MIC90, >64 µg/mL). BI 397 exhibited bacteriostatic activity (like the vancomycin control) vs. most species, but was bactericidal against tested Streptococcus pneumoniae. In vitro testing conditions with blood supplemented or free protein containing media elevated BI 397 MIC results, and the 30-µg disk seems acceptable for further disk diffusion test development. Animal pharmacokinetic data published elsewhere suggest that BI 397 may be dosed less frequently than teicoplanin and the results of early studies in humans are awaited with interest, especially when treating teicoplanin-refractory coagulase-neg. staphylococci.

Refine Search

Search Results -

Terms	Documents
L1 near5 protein	18

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L3

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, February 27, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L3	L1 near5 protein	18	L3
L2	L1 and protein	39	L2
L1	dalbavancin	58	L1

END OF SEARCH HISTORY